122 related articles for article (PubMed ID: 21911719)
1. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer.
Fairfield KM; Murray K; Lucas FL; Wierman HR; Earle CC; Trimble EL; Small L; Warren JL
J Clin Oncol; 2011 Oct; 29(29):3921-6. PubMed ID: 21911719
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer.
Fairfield KM; Murray K; LaChance JA; Wierman HR; Earle CC; Trimble EL; Warren JL
Gynecol Oncol; 2014 Sep; 134(3):473-7. PubMed ID: 24952367
[TBL] [Abstract][Full Text] [Related]
3. Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis.
Vogel TJ; Jeon C; Karlan B; Walsh C
Gynecol Oncol; 2016 Feb; 140(2):285-8. PubMed ID: 26691221
[TBL] [Abstract][Full Text] [Related]
4. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
5. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
Wright JD; Herzog TJ; Neugut AI; Burke WM; Lu YS; Lewin SN; Hershman DL
Obstet Gynecol; 2012 Oct; 120(4):871-81. PubMed ID: 22996105
[TBL] [Abstract][Full Text] [Related]
6. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Thrall MM; Gray HJ; Symons RG; Weiss NS; Flum DR; Goff BA
Gynecol Oncol; 2011 Jul; 122(1):100-6. PubMed ID: 21496889
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
8. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer.
Dinkelspiel HE; Tergas AI; Zimmerman LA; Burke WM; Hou JY; Chen L; Hillyer G; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2015 May; 137(2):203-9. PubMed ID: 25703674
[TBL] [Abstract][Full Text] [Related]
9. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
10. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Vogel TJ; Goodman MT; Li AJ; Jeon CY
Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
[TBL] [Abstract][Full Text] [Related]
11. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
12. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Australian Ovarian Cancer Study Group ; Webb P;
Gynecol Oncol; 2013 May; 129(2):310-7. PubMed ID: 23403164
[TBL] [Abstract][Full Text] [Related]
13. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
Gillen J; Gunderson C; Greenwade M; Rowland M; Ruskin R; Ding K; Crim A; Walter A; White E; Moore K
Gynecol Oncol; 2017 Apr; 145(1):32-36. PubMed ID: 28087143
[TBL] [Abstract][Full Text] [Related]
14. Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.
Doll KM; Pinheiro LC; Reeve BB
Gynecol Oncol; 2017 Feb; 144(2):348-353. PubMed ID: 27988047
[TBL] [Abstract][Full Text] [Related]
15. Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the Medicare population.
Fairfield KM; Lucas FL; Earle CC; Small L; Trimble EL; Warren JL
Cancer; 2010 Oct; 116(20):4840-8. PubMed ID: 20578182
[TBL] [Abstract][Full Text] [Related]
16. Completion of therapy by Medicare patients with stage III colon cancer.
Dobie SA; Baldwin LM; Dominitz JA; Matthews B; Billingsley K; Barlow W
J Natl Cancer Inst; 2006 May; 98(9):610-9. PubMed ID: 16670386
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer outcomes: Predictors of early death.
Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
[TBL] [Abstract][Full Text] [Related]
18. Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study.
Wallace SK; Lin JF; Cliby WA; Leiserowitz GS; Tergas AI; Bristow RE
J Natl Compr Canc Netw; 2016 May; 14(5):539-50. PubMed ID: 27160232
[TBL] [Abstract][Full Text] [Related]
19. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy.
Baxter NN; Durham SB; Phillips KA; Habermann EB; Virning BA
J Am Geriatr Soc; 2009 Mar; 57(3):403-11. PubMed ID: 19278395
[TBL] [Abstract][Full Text] [Related]
20. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
Anuradha S; Donovan PJ; Webb PM; Brand AH; Goh J; Friedlander M; Oehler MK; Quinn M; Steer C; Jordan SJ
Acta Oncol; 2016; 55(2):226-33. PubMed ID: 26079434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
